Safety Study in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Receiving Betaferon or Rebif
Status:
Completed
Trial end date:
2008-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the injection site reaction and injection site pain
after subcutaneous administration of either Betaferon 250µg or Rebif 44µg using different
autoinjectors.